Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis

CONCLUSIONS: Given diversity and potential biases, oncologists should base immunotherapy decisions on professional expertise and patient characteristics.REGISTRATION: PROSPERO registration number: CRD42023453484.PMID:38532600 | DOI:10.1080/14737140.2024.2336106

Source: Expert Review of Anticancer Therapy - March 27, 2024 Category: Cancer & Oncology Authors: Shuting Cui Xiaozhe Sun Junxi Gao Source Type: research